Associations between the CYP17, CYPIB1, COMT and SHBG polymorphisms and serum sex hormones in post-menopausal breast cancer survivors

Breast Cancer Research and Treatment

Volumn 105, Issue 1, 2007, Pages 45-54

  Abrahamson, Page E ^a,b   Tworoger, Shelley S ^c   Aiello, Erin J ^d   Bernstein, Leslie ^e   Ulrich, Cornelia M ^a,b   Gilliland, Frank D ^e   Stanczyk, Frank Z ^e   Baumgartner, Richard ^f   Baumgartner, Kathy ^f   Sorensen, Bess ^a,b   Ballard Barbash, Rachel ^g   McTiernan, Anne ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF LOUISVILLE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; COMT; CYP17; CYP1B1; Estrogen; SHBG; Testosterone

Indexed keywords

ASPARAGINE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 1B1; ESTRADIOL; ESTRONE; PRASTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISPANIC; HORMONE BLOOD LEVEL; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RADIOIMMUNOASSAY; SEX HORMONE DETERMINATION; TESTOSTERONE BLOOD LEVEL; UNITED STATES; WILD TYPE;

ADOLESCENT; ADULT; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEHYDROEPIANDROSTERONE; FEMALE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RADIOIMMUNOASSAY; SEX HORMONE-BINDING GLOBULIN; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE;

EID: 34548011710     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9426-2     Document Type: Article

References (42)

1. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17-35
2. Bernstein L, Ross RL (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15:48-65
3. Yue W, Santen RJ, Wang J-P, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86(3-5):477-486
4. Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67-73
5. The Endogenous Hormones, Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616
6. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451-1467
7. Rock CL, Demark-Wahnefried W (2002) Can lifestyle modification increase survival in women diagnosed with breast cancer? J Nutr 132(11 Suppl):3504S-3507S
8. Sharp L, Cardy AH, Cotton SC, Little J (2004) CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. A HuGE review. Am J Epidemiol 160(8):729-740
9. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063-1065
10. Bailey LR, Roodi N, Dupont WD, Parl FF (1998) Associations of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 58(22):5038-5041
11. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203-232
12. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20(8):1607-1613
13. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000) Cytochrome P450 IBI (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60:3440-3444
14. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF (2001) Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 61(18):6716-6722
15. Becchis M, Frairia R, Ferrera P, Fazzari A, Ondei S, Alfarano A, Coluccia C, Biglia N, Sismondi P, Fortunati N (1999) The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. Breast Cancer Res Treat 54(2):101-107
16. Hardy DO, Carino C, Catterall JF, Larrea F (1995) Molecular characterization of a genetic variant of the steroid hormone-binding globulin gene in heterozygous subjects. J Clin Endocrinol Metab 80(4):1253-1256
17. Larrea F, Carino C, Hardy DO, Musto NA, Catterall JF (1995) Genetic variations in human testosterone-estradiol binding globulin. J Steroid Biochem Mol Biol 53(1-6):553-559
18. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PDP, Easton DF, Day NE, Ponder BAJ (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96(12):936-945
19. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A (2004) Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13(1):94-101
20. McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, Gilliland F, Stanczyk FZ, Yasui Y, Ballard-Barbash R (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21:1961-1966
21. Marchbanks PA, Mcdonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, Liff JM, Wingo PA, Burkman RT, Folger SG, Berline JA et al (2002) The NICHD women's contraceptive and reproductive experiences study: methods and operational results. Ann Epidemiol 12(4):213-221
22. Meeske K, Press M, Patel A, Bernstein L (2004) Impact of reproductive factors and lactation on breast carcinoma in situ risk. Int J Cancer 110(1):102-109
23. McShane LM, Dorgan JF, Greenhut S, Damato JJ (1996) Reliability and validity of serum sex hormone measurements. Cancer Epidemiol Biomarkers Prev 5:923-928
24. Falk RT, Dorgan JF, Kahle L, Potischman N, Longcope C (1997) Assay reproducibility of hormone measurements in postmenopausal women. Cancer Epidemiol Biomarkers Prev 6:429-432
25. Edwards AM, Hunter SV, Hankin RC (1993) Gene rearrangement analysis by nonorganic extraction and chemiluminescent detection. Lab Med 24(10):629-635
26. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59(5):1015-1020
27. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14(5-6):143-149
28. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57(24):5493-5497
29. Sodergard R, Backstrom T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16:801-810
30. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2001) A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 61(10):3955-3960
31. Travis RC, Churchman M, Edwards SA, Smith G, Verkasalo PK, Wolf CR, Wolf H, Key TJ (2004) No association of polymorphisms in CYP17, CYP19, and HSD17-B1 with plasma estradiol concentrations in 1,090 British women. Cancer Epidemiol Biomarkers Prev 13(12):2282-2284
32. Somner J, McLellan S, Cheung J, Mak YT, Frost ML, Knapp KM, Wierzbicki AS, Wheeler M, Fogelman I, Ralston SH, Hampson GN (2004) Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 89(1):344-351
33. Marszalek B, Lacinski M, Babych N, Capla E, Biernacka-Lukanty J, Warenik-Szymankiewicz A, Trzeciak WH (2001) Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5'-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 15(2):123-128
34. Small CM, Marcus M, Sherman SL, Sullivan AK, Manatunga AK, Feigelson HS (2005) CYP17 genotype predicts serum hormone levels among pre-menopausal women. Hum Reprod 20(8):2162-2167
35. Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, LeMarchand L (2005) Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 14(6):1521-1527
36. García-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF (2002) Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 102(2):172-178
37. Paracchini V, Pedotti P, Raimondi S, Garte S, Bradlow HL, Sepkovic DW, Taioli E (2005) A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med 43(7):702-706
38. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M (2002) Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 61:586-594
39. Cui Y, Shu XO, Cai Q, Jin F, Cheng JR, Cai H, Gao YT, Zheng W (2005) Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene. Cancer Epidemiol Biomarkers Prev 14(5):1096-1101
40. Haiman CA, Riley SE, Freedman ML, Setiawan VW, Conti DV, Le Marchand L (2005) Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating SHBG levels among postmenopausal women: the multiethnic cohort. J Clin Endocrinol Metab 90(4):2198-2204
41. Lagakos SW (2006) The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354(16):1667-1669
42. Wen W, Cai Q, Shu XO, Cheng JR, Parl F, Pierce L, Gao YT, Zheng W (2005) Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the Shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 14(2):329-335